CoChat

Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2

Open access

Preprint — published as 10.1038/s42003-023-05239-6

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Insulin-like Growth Factor-2 (IGF2) is important for the regulation of human embryonic growth and development, and for adults’ physiology. Incorrect processing of the IGF2 precursor, pro-IGF2(156), leads to the formation of two IGF2 proforms, big-IGF2(87) and big-IGF2(104). Unprocessed and mainly non-glycosylated IGF2 proforms are found at abnormally high levels in certain diseases, but their mode of action is still unclear. Here, we found that pro-IGF2(156) has the lowest ability to form its inactivating complexes with IGF-Binding Proteins and has higher proliferative properties in cells than IGF2 and other IGF prohormones. We also showed that big-IGF2(104) has a seven-fold higher binding affinity for the IGF2 receptor than IGF2, and that pro-IGF2(87) binds and activates specific receptors and stimulates cell growth similarly to the mature IGF2. The properties of these pro-IGF2 forms, especially of pro-IGF2(156) and big-IGF2(104), indicate them as hormones that may be associated with human diseases related to the accumulation of IGF-2 proforms in the circulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2023.01.16.524179

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Primary sequence of pre-pro-IGF2. Sites where pro-IGF2 is cleaved into big-IGF2(87) and big-IGF2(104) are marked in red.
Fig. 1 Primary sequence of pre-pro-IGF2. Sites where pro-IGF2 is cleaved into big-IGF2(87) and big-IGF2(104) are marked in red.CC BY · PubMed Central
Fig. 2 Experimental CD spectra of IGF2 derivatives. CD spectra of IGF2 (black), big-IGF2(87) (red), big-IGF2(104) (blue), and pro-IGF2(156) (green) recorded in 0.1% CH3COOH (a). Secondary structure content (SSC, in %) estimated using BeStSel according to CD spectra (b).
Fig. 2 Experimental CD spectra of IGF2 derivatives. CD spectra of IGF2 (black), big-IGF2(87) (red), big-IGF2(104) (blue), and pro-IGF2(156) (green) recorded in 0.1% CH3COOH (a). Secondary structure content (SSC, in %) estimated using BeStSel according to CD spectra (b).CC BY · PubMed Central
Fig. 3 Binding affinities and receptor activation abilities of IGF2 derivatives for IR-A, IR-B and IGF-1R. Binding affinity (cyan) and receptor autophosphorylation (gray) of human insulin (HI), IGF1, IGF2 and big-IGF2(87), big-IGF2(104), and pro-IGF2(156) to IR-A (a), IR-B (c) and IGF-1R (e); Phosphorylation of Akt (green) and Erk 1/2 (orange) on IR-A (b), IR-B (d) and IGF-1R (f) overexpressing cells. Data are presented as means ± S.D. relatively to the binding and stimulation induced by insulin (on IR-A and IR-B) or IGF1 (on IGF1R). Significant differences between marked values determined using Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Fig. 3 Binding affinities and receptor activation abilities of IGF2 derivatives for IR-A, IR-B and IGF-1R. Binding affinity (cyan) and receptor autophosphorylation (gray) of human insulin (HI), IGF1, IGF2 and big-IGF2(87), big-IGF2(104), and pro-IGF2(156) to IR-A (a), IR-B (c) and IGF-1R (e); Phosphorylation of Akt (green) and Erk 1/2 (orange) on IR-A (b), IR-B (d) and IGF-1R (f) overexpressing cells. Data are presented as means ± S.D. relatively to the binding and stimulation induced by insulin (on IR-A and IR-B) or IGF1 (on IGF1R). Significant differences between marked values determined using Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.CC BY · PubMed Central
Fig. 4 Relative binding affinities of IGF2 derivatives for M6P/IGF2R. a Binding to immobilized domain 11 of M6P/IGF2R; b Binding to M6P/IGF2R in R- cells of IGF1, IGF2, big-IGF2(87), big-IGF2(104), and pro-IGF2(156). Data are presented as means ± S.D., relative to the binding affinity of IGF2. Significant differences between marked values determined using Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), ****p < 0.0001.
Fig. 4 Relative binding affinities of IGF2 derivatives for M6P/IGF2R. a Binding to immobilized domain 11 of M6P/IGF2R; b Binding to M6P/IGF2R in R- cells of IGF1, IGF2, big-IGF2(87), big-IGF2(104), and pro-IGF2(156). Data are presented as means ± S.D., relative to the binding affinity of IGF2. Significant differences between marked values determined using Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), ****p < 0.0001.CC BY · PubMed Central
Fig. 5 Relative binding affinities of IGF2, pro-IGFs and IGF1 to form binary and ternary complexes with IGFBP3 and IGFBP3:ALS. a Formation of binary complexes with IGBP3; b Formation of ternary complexes with IGFBP3:ALS. Data are presented as means ± S.D., relative to the binding affinity of IGF2. Significant differences between marked values determined using Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), *p < 0.05, **p < 0.01.
Fig. 5 Relative binding affinities of IGF2, pro-IGFs and IGF1 to form binary and ternary complexes with IGFBP3 and IGFBP3:ALS. a Formation of binary complexes with IGBP3; b Formation of ternary complexes with IGFBP3:ALS. Data are presented as means ± S.D., relative to the binding affinity of IGF2. Significant differences between marked values determined using Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), *p < 0.05, **p < 0.01.CC BY · PubMed Central
Fig. 6 Stimulation of phosphorylation of Akt and Erk 1/2. Stimulation of phosphorylation of intracellular Akt (green) and Erk 1/2 (orange) proteins in murine fibroblasts with deleted igf1r gene (R- cells) (a) and in MC3T3-E1 preosteoblasts (b) by human insulin (HI), IGF1, IGF2, big-IGF2(87), big-IGF2(104), and pro-IGF2(156). Data are presented as means ± S.D., relative to the signal in non-stimulated cells. Significant differences between marked values determined using Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Fig. 6 Stimulation of phosphorylation of Akt and Erk 1/2. Stimulation of phosphorylation of intracellular Akt (green) and Erk 1/2 (orange) proteins in murine fibroblasts with deleted igf1r gene (R- cells) (a) and in MC3T3-E1 preosteoblasts (b) by human insulin (HI), IGF1, IGF2, big-IGF2(87), big-IGF2(104), and pro-IGF2(156). Data are presented as means ± S.D., relative to the signal in non-stimulated cells. Significant differences between marked values determined using Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.CC BY · PubMed Central
Fig. 7 Analysis of intracellular calcium mobilization by IGF2, IGF1 and IGF2 prohormones. R- cells (a), U2OS cells (b), and MC3T3-E1 cells (c) by IGF2 (black), IGF1 (red), big-IGF2(87) (orange), big-IGF2(104) (blue), pro-IGF2(156) (green). Data represent the 340/380 (averages of duplicate measurements plus error ranges) ratio recorded for 70 s by FlexStation 3 and n = 2 independent experiments with 2 replicates.
Fig. 7 Analysis of intracellular calcium mobilization by IGF2, IGF1 and IGF2 prohormones. R- cells (a), U2OS cells (b), and MC3T3-E1 cells (c) by IGF2 (black), IGF1 (red), big-IGF2(87) (orange), big-IGF2(104) (blue), pro-IGF2(156) (green). Data represent the 340/380 (averages of duplicate measurements plus error ranges) ratio recorded for 70 s by FlexStation 3 and n = 2 independent experiments with 2 replicates.CC BY · PubMed Central
Fig. 8 Differentiation of hBMSC-TERT osteoblasts after treatment with IGF2 proforms. IGF2 (a), big-IGF2(87) (b), big-IGF2(104) (c), pro-IGF2(156) (d), and gly pro-IGF2(156) (e). The data were evaluated using quantification of alkaline phosphatase (ALP) activity, normalized to cell viability presented as a fold change (F.C.) over non-induced cells (day 8), n = 2 independent experiments with 6 replicates (only gly pro-IGF2(156) with 4 replicates). Data are presented as mean ± SEM (n = 6 (or 4) per group), Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), *p < 0.05, **p < 0.01, ****p < 0.0001. A.U. means arbitrary units.
Fig. 8 Differentiation of hBMSC-TERT osteoblasts after treatment with IGF2 proforms. IGF2 (a), big-IGF2(87) (b), big-IGF2(104) (c), pro-IGF2(156) (d), and gly pro-IGF2(156) (e). The data were evaluated using quantification of alkaline phosphatase (ALP) activity, normalized to cell viability presented as a fold change (F.C.) over non-induced cells (day 8), n = 2 independent experiments with 6 replicates (only gly pro-IGF2(156) with 4 replicates). Data are presented as mean ± SEM (n = 6 (or 4) per group), Ordinary one-way ANOVA (Dunnett´s multiple comparisons test), *p < 0.05, **p < 0.01, ****p < 0.0001. A.U. means arbitrary units.CC BY · PubMed Central
Fig. 9 Alizarin red S staining of hBMSC-TERT differentiated into osteoblasts. Alizarin red S staining of hBMSC-TERT differentiated into osteoblasts for 11 days in vitro (scale bar 200 µm); ×10 magnification. The cells were treated with increasing concentrations of non-glycosylated prohormones and native IGF2.
Fig. 9 Alizarin red S staining of hBMSC-TERT differentiated into osteoblasts. Alizarin red S staining of hBMSC-TERT differentiated into osteoblasts for 11 days in vitro (scale bar 200 µm); ×10 magnification. The cells were treated with increasing concentrations of non-glycosylated prohormones and native IGF2.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 69

  1. 10.1016/j.tins.2011.12.007 · DOI · Paper page
  2. 10.1186/S40792-018-0508-2 · DOI
  3. 10.1007/s00216-021-03423-3 · DOI
  4. 10.1210/jc.80.9.2700 · DOI · Paper page
  5. 10.1210/jc.2013-3525 · DOI
  6. 10.1677/joe.0.1650253 · DOI · Paper page
  7. 10.1056/NEJM198812013192202 · DOI · Paper page
  8. 10.1073/pnas.86.17.6778 · DOI · Paper page
  9. 1994, Unglycosylated Big Igf-Ii in Nonislet Cell Tumor Hypoglycemia (Nicth) and Its Serum Binding, Insulin-Like Growth Factors and Their Regulatory Proteins, 1056, 77
  10. 10.1073/pnas.90.12.5823 · DOI · Paper page
  11. 10.1007/BF02935648 · DOI
  12. 10.1677/ERC-07-0161 · DOI · Paper page
  13. 10.1074/jbc.273.29.18443 · DOI · Paper page
  14. 10.1210/er.2012-1033 · DOI · Paper page
  15. 1999, Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells, MolCell Biology, 19, 3278
  16. 10.1007/s001250050951 · DOI
  17. 10.1016/j.ghir.2006.05.003 · DOI · Paper page
  18. 10.1074/jbc.M112.432013 · DOI
  19. 10.1074/jbc.272.44.27936 · DOI
  20. 10.1523/JNEUROSCI.2730-05.2006 · DOI · Paper page
  21. 10.1074/jbc.M116.741041 · DOI
  22. 10.2169/internalmedicine.9287-17 · DOI
  23. 10.1210/jc.83.8.2875 · DOI · Paper page
  24. 10.3390/cells8101207 · DOI
  25. 10.2169/internalmedicine.54.4945 · DOI
  26. 10.1530/eje.0.1390317 · DOI
  27. 10.1677/JOE-07-0619 · DOI
  28. 10.1530/EJE-13-1012 · DOI · Paper page
  29. 10.1016/j.ando.2018.01.005 · DOI
  30. 10.1210/edrv-16-1-3 · DOI · Paper page
  31. 10.1002/bip.360221211 · DOI · Paper page
  32. 10.1016/j.ecl.2012.04.013 · DOI · Paper page
  33. 10.1210/jc.2018-00593 · DOI
  34. 10.1210/jc.87.8.3867 · DOI · Paper page
  35. 10.1172/JCI1111 · DOI · Paper page
  36. 10.1038/s41467-022-32214-2 · DOI
  37. 2006, Insulin-like growth factors Seminars in Medicine of the Beth Israel Deaconess Medical Center, 336, 633
  38. 10.1016/j.molmet.2021.101245 · DOI · Paper page
  39. 10.1074/jbc.RA119.010072 · DOI
  40. 10.1210/en.2010-0784 · DOI
  41. 10.1210/jc.86.8.3665 · doi:10.1210/jc.86.8.3665 · Paper page
  42. 10.1093/nar/gkac345 · DOI · Paper page
  43. 10.1093/nar/gky497 · DOI · Paper page
  44. 10.1038/s41592-022-01488-1 · doi:10.1038/s41592-022-01488-1 · Paper page
  45. 10.1093/bioinformatics/bty1057 · DOI · Paper page
  46. 10.1074/jbc.270.38.22639 · DOI · Paper page
  47. 10.1074/jbc.M111.252478 · DOI · Paper page
  48. 2021, A case of nonislet cell tumor hypoglycemia associated with malignant mesothelioma requiring a multifaceted approach for optimal glycemic control, Clinical Case Reports, 9, 10
  49. 10.1371/journal.pone.0238393 · DOI
  50. 10.1016/j.ghir.2009.11.001 · DOI
  51. 10.1158/1078-0432.CCR-18-2697 · DOI
  52. 10.1128/MCB.14.6.3604 · DOI · Paper page
  53. 10.1038/nbt0602-592 · DOI · Paper page
  54. 10.1016/j.neurobiolaging.2016.04.006 · DOI · Paper page
  55. 10.1002/wsbm.1196 · DOI
  56. 10.1507/endocrj.K08E-062 · DOI
  57. 10.1016/j.celrep.2019.04.066 · DOI · Paper page
  58. 10.1074/jbc.272.8.4804 · DOI
  59. 10.1002/biof.1623 · DOI
  60. 10.1016/j.ghir.2014.08.002 · DOI
  61. 10.1016/0002-9343(92)90165-8 · DOI
  62. 10.1126/sciadv.aaz1466 · DOI
  63. 10.1126/science.1228633 · DOI
  64. 10.1016/j.str.2007.07.007 · DOI
  65. 10.1016/j.str.2020.05.002 · DOI
  66. 10.1210/en.137.7.2766 · doi:10.1210/en.137.7.2766
  67. 10.7554/eLife.54781 · DOI · Paper page
  68. 10.1107/S1399004714017775 · DOI
  69. 10.1172/JCI116152 · DOI · Paper page

Metadata

Authors
Potalitsyn, P., Mrázková, L., Selicharová, I., Tencerová, M., Ferenčáková, M., Chrudinová, M., Brzozowski, A. M., Marek, A., Kaminský, J., Jiráček, J., & Žáková, L.
Affiliations
  • Czech Academy of Sciences (CZ)
  • University of York (GB)
Corresponding author
Žáková, Lenka
Venue
Communications Biology
Publisher
openRxiv
Published
2023-01-18
Volume
6
Issue
1
Pages
863-863
ISSN
2399-3642 (ISSN-L)
OpenAlex
W4386001747
Cited by
12
References
1
Citations by year
2026: 5 · 2025: 5 · 2024: 1 · 2023: 1
FWCI
2.45
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Communications Biology (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Research Councils UK (BB/W003783/1)
  • European Commission (CZ.02.1.01, LX22NPO5104)
  • Grantová Agentura České Republiky (CZ.02.1.01/0.0, CZ.02.1.01/0.0/0.0/16019/0000729, GA19-14069S, CZ.02.1.01, LX22NPO5104)
  • Akademie Věd České Republiky (LX22NPO5104, 6138963, RVO:6138963)
  • Medical Research Council (MR/R009066/1)
  • Biotechnology and Biological Sciences Research Council (BB/W003783/1)
  • European Regional Development Fund (02.1.01/0.0/0.0, .02.1.01/0.0/0.0/16_019/0000729, CZ.02.1.01/ 0.0/0.0/16_019/0000729, CZ.02, 16_019/0000729, CZ.02.1.01, CZ.02.1.01/0.0/0.0, /16_019)
  • NextGenerationEU
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Syndromes and Imprinting
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
Keywords
insulin-like growth factor II, IGF binding proteins, cell proliferation, mitogenic activity
MeSH terms
Adult, Cell Cycle, Humans, Insulin-Like Growth Factor II, Mitogens, Intercellular Signaling Peptides and Proteins, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2. https://app.cochat.ai/papers/10.1101/2023.01.16.524179
The paper
Potalitsyn, P., Mrázková, L., Selicharová, I., Tencerová, M., Ferenčáková, M., Chrudinová, M., Brzozowski, A. M., Marek, A., Kaminský, J., Jiráček, J., & Žáková, L. (2023). Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2. Communications Biology. https://doi.org/10.1101/2023.01.16.524179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.